Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma? (PREDIR)

Fondation Ophtalmologique Adolphe de Rothschild

Status: Enrolling

Conditions: Retinoblastoma

Treatments: Device: Dynamic contrast-enhanced MRI

Study type: Observational

Funder types: NETWORK

Identifiers

NCT03267459

ALR_2017_2

Details and patient eligibility

About

Retinoblastoma is the most frequent intraocular tumor in children and represents 6% of all pediatric cancers before the age of 5 years-old. The outcome is now excellent with 95 to 97% of 5-years survival rate. Conservative treatments are being more and more used, and intra arterial chemotherapy is one of the adjuvant treatments proposed to the children. The treatment is efficient in most cases, but a small proportion of children will have an early progression after treatment. MRI is used for the diagnosis of retinoblastoma. We aim to find prognostic factors using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for early identification of children response to intra arterial chemotherapy.

Enrollment: 60 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• grade B to D retinoblastoma
• prescription of intra arterial chemotherapy

Exclusion criteria

• none